Page 4 - Dr Reddy's Laboratories

Sensex rises 203 pts, Nifty ends near 17,800; Maruti zooms 5%, RIL 3%

Stock market wrap: Reliance alone contributed 231 points to the 30-share benchmark. Maruti, M&M and NTPC were the other major gainers. The Metal and IT sector witnessed selling pressure.

Q2FY23 preview: Modest revenue growth, Ebitda decline seen in pharma cos

While domestic market demand is strong, analysts expect higher raw material and freight costs to affect business in US, other countries; healthy YoY growth seen in hospitals and diagnostics

Wockhardt likely to sell India business to cut debt, focus on UK: Analysts

Company left with low-margin brands in India after selling profitable ones

Indian generic formulation-makers level of capex declining: Candle Partners

Candle Partners study shows that from the peak of 30% of gross block in FY16, the capex is down to 9-10% of gross block

Adani Green could replace Dr Reddy's in Sensex during December review

If added, Adani Green will be the first stock from the group in Sensex. After the inclusion of Adani Enterprises by September-end, Nifty will have two Adani group constituents

At least 8 Indian companies working to develop monkeypox vaccine: Report

Among the companies that are working with ICMR are Serum Institute of India (SII), Reliance Life Sciences, Dr Reddy's Laboratories, and Biological E

Indian Covid vaccine makers eye regulator nod for universal boosters

Plans afoot to seek regulator nod for universal boosters

Strong India growth boosts DRL Q1 profit by 108% to Rs 1,188 crore

The DRL stock was down marginally (0.73 per cent) to Rs 4,254 on the BSE on Thursday

Top headlines: Dr Reddy's Q1 PAT up 108%; Adani Capital IPO likely in 2024

Bajaj Finserv on Thursday reported a 57 per cent jump in net profit at Rs 1,309 crore in the first quarter ended June 30, on healthy earnings by its subsidiary companies.

Dr Reddy's Q1 revenue may grow up to 10% YoY, margins may expand: Analysts

Dr Reddy's Labs Q1 results preview: Analysts said that despite pricing pressures in the US, the company is likely to have recorded steady growth in this segment due to a ramp-up of new products.

Dr Reddy's Laboratories eyes place among top five domestic pharma players

The US would continue to remain an important geography, but the firm says it hopes to double its revenues from China and grow revenues five-fold in Brazil in the next five years

From DRL to Glenmark, pharma companies see steady revenue growth in Russia

Strong sales in Q4 during war aided by 'stocking up of inventory'

Launches, base biz expansion tonic for Dr Reddy's double-digit growth

While the company's bottom line grew 10.5% annually over the 2016-17 through 2021-22 (FY22) period, it is expected to register thrice that growth rate over next two years, observes ICICI Securities

No changes in Sensex composition, Dr Reddy's remains in benchmark index

The market was expecting Tata Motors to replace DRL in the 30-share index

Dr Reddy's Labs Q4 PAT falls 76% on pricing pressure, low export benefit

Dr Reddy's Q4 results: The revenue was up 15% to Rs 5,437 crore for the quarter under review

Dr Reddy's plans new brands in Russia, says no issue with funds in country

The company's Russian revenue was at Rs 686 crore for Q4FY22, a year-on-year growth of 70%.

Dr Reddy's Q4 PAT may rise 28% YoY; margins likely to fall, say analysts

The pharmaceutical giant may witness some impact due to its large exposure of the business to Russia, and CIS regions.

Dr Reddy inks $61-mn deal to acquire Cidmus brand in India from Novartis

The acquisition of Cidmus is yet another move by drug major to widen access of healthcare professionals and patients to well-established brands

Sputnik Light may soon be only version available in India amid low demand

Meanwhile, local manufacturing partners have either halted or reduced production of Sputnik Light owing to low demand

Valuations turning attractive for Dr Reddy's as company outperforms sector

US price erosion, India growth trends would be keenly tracked